KR102613106B1 - Ｂ―세포 악성종양의 치료를 위한 세르둘라티닙 - Google Patents

Ｂ―세포 악성종양의 치료를 위한 세르둘라티닙 Download PDF

Info

Publication number
KR102613106B1
KR102613106B1 KR1020177036772A KR20177036772A KR102613106B1 KR 102613106 B1 KR102613106 B1 KR 102613106B1 KR 1020177036772 A KR1020177036772 A KR 1020177036772A KR 20177036772 A KR20177036772 A KR 20177036772A KR 102613106 B1 KR102613106 B1 KR 102613106B1
Authority
KR
South Korea
Prior art keywords
cerdulatinib
composition
patient
mutation
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177036772A
Other languages
English (en)
Korean (ko)
Other versions
KR20180011210A (ko
Inventor
안잘리 판데이
그레고리 코피
자넷 리즈
Original Assignee
포톨라 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포톨라 파마슈티컬스, 인코포레이티드 filed Critical 포톨라 파마슈티컬스, 인코포레이티드
Publication of KR20180011210A publication Critical patent/KR20180011210A/ko
Application granted granted Critical
Publication of KR102613106B1 publication Critical patent/KR102613106B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177036772A 2015-05-29 2016-05-27 Ｂ―세포 악성종양의 치료를 위한 세르둘라티닙 Active KR102613106B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562168530P 2015-05-29 2015-05-29
US62/168,530 2015-05-29
US201562263582P 2015-12-04 2015-12-04
US62/263,582 2015-12-04
PCT/US2016/034861 WO2016196385A1 (en) 2015-05-29 2016-05-27 Cerdulatinib for the treatment of b-cell malignancies

Publications (2)

Publication Number Publication Date
KR20180011210A KR20180011210A (ko) 2018-01-31
KR102613106B1 true KR102613106B1 (ko) 2023-12-12

Family

ID=57441822

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177036772A Active KR102613106B1 (ko) 2015-05-29 2016-05-27 Ｂ―세포 악성종양의 치료를 위한 세르둘라티닙

Country Status (9)

Country Link
US (2) US20180147203A1 (https=)
EP (1) EP3302485B1 (https=)
JP (2) JP7258462B2 (https=)
KR (1) KR102613106B1 (https=)
CN (1) CN107683139A (https=)
AU (1) AU2016270658B2 (https=)
CA (1) CA2987324C (https=)
ES (1) ES2958412T3 (https=)
WO (1) WO2016196385A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6833816B2 (ja) 2015-08-12 2021-02-24 ポートラ ファーマシューティカルズ， インコーポレイテッド 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
AU2016363005A1 (en) 2015-12-04 2018-07-05 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers
US20180065317A1 (en) 2016-09-06 2018-03-08 Cc3D Llc Additive manufacturing system having in-situ fiber splicing
WO2018189566A1 (en) * 2017-04-10 2018-10-18 Dorian Bevec Use of a chemical compound as a therapeutic agent
EP3788035B1 (en) 2018-05-04 2024-08-07 Alexion Pharmaceuticals, Inc. Solid forms of cerdulatinib
EP3787628A1 (en) * 2018-05-04 2021-03-10 Portola Pharmaceuticals, Inc. Methods for treating lymphoma
US10851087B2 (en) 2018-05-04 2020-12-01 Portola Pharmaceuticals, Inc. Synthesis of cerdulatinib
CN108743947B (zh) * 2018-07-04 2020-12-15 复旦大学附属肿瘤医院 一种治疗b细胞淋巴瘤的药物组合物
US20230181581A1 (en) * 2020-05-26 2023-06-15 Alexion Pharmaceuticals, Inc. Circulating b cell subpopulations in indolent b cell lymphoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130040973A1 (en) 2011-08-10 2013-02-14 Incyte Corporation JAK PI3K/mTOR COMBINATION THERAPY
WO2014004858A1 (en) 2012-06-27 2014-01-03 Novomer, Inc. Catalysts and methods for polyester production
WO2016004858A1 (zh) 2014-07-07 2016-01-14 乐视致新电子科技（天津）有限公司 数据处理方法、装置及移动终端设备

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255756A (ja) 1984-06-01 1985-12-17 Ikeda Mohandou:Kk アミノアルキルフエノキシ誘導体
WO1995032963A1 (en) 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
AU1507199A (en) 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
WO2003037352A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003244098A1 (en) 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
MX2009000769A (es) 2006-07-21 2009-01-28 Novartis Ag Compuestos de 2,4-di(arilaminio)-pirimidin-5-carboxamida como inhibidores de cinasas jak.
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EA024109B1 (ru) 2008-04-16 2016-08-31 Портола Фармасьютиклз, Инк. Ингибиторы протеинкиназ
AR076550A1 (es) 2009-05-06 2011-06-22 Portola Pharm Inc Inhibidores de la janus tirosina kinasa (jak)
WO2012045020A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
CN104704129A (zh) * 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
SG11201503459SA (en) 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
JP6833816B2 (ja) 2015-08-12 2021-02-24 ポートラ ファーマシューティカルズ， インコーポレイテッド 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
AU2016363005A1 (en) * 2015-12-04 2018-07-05 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130040973A1 (en) 2011-08-10 2013-02-14 Incyte Corporation JAK PI3K/mTOR COMBINATION THERAPY
WO2014004858A1 (en) 2012-06-27 2014-01-03 Novomer, Inc. Catalysts and methods for polyester production
WO2016004858A1 (zh) 2014-07-07 2016-01-14 乐视致新电子科技（天津）有限公司 数据处理方法、装置及移动终端设备

Also Published As

Publication number Publication date
ES2958412T3 (es) 2024-02-08
EP3302485B1 (en) 2023-07-12
US12350269B2 (en) 2025-07-08
JP2021152076A (ja) 2021-09-30
EP3302485A1 (en) 2018-04-11
JP2018520117A (ja) 2018-07-26
AU2016270658B2 (en) 2021-08-12
US20220096471A1 (en) 2022-03-31
WO2016196385A1 (en) 2016-12-08
AU2016270658A1 (en) 2018-01-04
JP7258462B2 (ja) 2023-04-17
CA2987324A1 (en) 2016-12-08
KR20180011210A (ko) 2018-01-31
CN107683139A (zh) 2018-02-09
CA2987324C (en) 2023-08-22
US20180147203A1 (en) 2018-05-31
EP3302485A4 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
KR102613106B1 (ko) Ｂ―세포 악성종양의 치료를 위한 세르둘라티닙
US11446300B2 (en) Cerdulatinib for treating hematological cancers
US20220226336A1 (en) Combination therapy for treating cancer
CA2998042C (en) Dactinomycin compositions and methods for the treatment of acute myeloid leukemia
HK1253804B (en) Cerdulatinib for the treatment of b-cell malignancies
HK1253804A1 (en) Cerdulatinib for the treatment of b-cell malignancies
HK1262118B (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK1262118A1 (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK40061501A (en) Combination therapy for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171220

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210428

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230321

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230920

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231208

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231208

End annual number: 3

Start annual number: 1

PG1601 Publication of registration